Evaluating the Market Position of Sitagliptin...

Evaluating the Market Position of Sitagliptin: Insights and Implications

Author Name : Mr. Gajanan Jyotilal Rathod, Mr. Suraj Parmeshwar Rajurkar, Dr. Karishma Arunrao Nikose, Mr. Suraj Dnyaneshwar Thakare, Miss Nikita Mohanrao Wakchaware, Miss Rani Rajendra Fasate, Miss Manisha Ramesh Chavhan

This study provides a comprehensive analysis of the marketed brands of sitagliptin tablets, a leading medication used in the management of type 2 diabetes mellitus. Sitagliptin, a DPP-4 inhibitor, is marketed under various brand names globally, with Januvia (by Merck & Co.) being the most prominent. The objective of this research is to compare the market shares and pricing strategies of sitagliptin tablets available in the pharmaceutical market. Type 2 diabetes mellitus (T2DM) represents a complex metabolic disorder characterized by insulin resistance, impaired insulin secretion, and chronic hyperglycemia. Sitagliptin exerts its antidiabetic effects by inhibiting DPP-4, an enzyme responsible for the degradation of incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Multiple pharmaceutical companies market sitagliptin under various brand names with different dosages and pricing. The data for selected brands containing sitagliptin was collected through market research, which included their price per tablet and unit sales. A comparison of different brands of sitagliptin tablets reveals varying market shares, with leading brands like Istavel, Sitabite, Sitara, Stigand, etc., holding significant dominance due to factors like pricing, efficacy, and brand reputation